CSTONE PHARMA-B

Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercialization.

Through a dual source of innovation consisting of internal R&D and external collaboration, the company has built a powerful anti-tumor drug pipeline with 14 drug candidates, including 4 products exclusively collaborated and authorized by Blueprint Medicine and Agios Pharmaceuticals. Together with the self-developed pipeline, the company has significant potential and synergistic effects for single and combination therapies. Of the drug candidates under development, 4 are in or close to critical trials. Cornerstone Pharmaceutical's business model is driven by clinical research and development, while rapidly establishing commercialization and production capacity.

The company received support from well-known investors, and both the A and B rounds of financing broke records in the biomedical field at the time, with a total amount of 412 million US dollars in the two rounds of financing.

With an experienced team, a promising R&D pipeline, a strong business model, and sustainable financial support, Cornerstone's vision is to become a world-renowned leading Chinese biopharmaceutical company by bringing innovative and differentiated oncology therapies to cancer patients around the world.